Previous Page
11-09 :: September 2011
nanotimes
Companies Facts
dustrial companies. He will succeed Richard Archu- leta who is stepping down after leading the company for the past four years.
atar Solar Technologies (QSTec) will build a US$1 billion polysilicon manufacturing plant
in Ras Laffan Industrial City. The plant is expected to produce 8,000 metric tons of polysilicon per year. QSTec expects the facility to be operational in the second half of 2013.
http://www.qf.org.qa/joint-ventures/qatar-solar-technologies
“Quantum dots are light emitting materials made via a precisely-controlled chemical synthesis process. The sophisticated nature of the manufacturing pro- cess, coupled with the need for a skilled educated workforce, makes Massachusetts an ideal place to locate a high-volume Quantum Dot manufacturing facility,” said Jason Carlson, QD Vision CEO.
D Vision, Inc., developer of nanotechnology- based optical products for displays and solid
state lighting, has relocated to a new, high-volume production facility in Lexington, Massachusetts to support new products launching in 2012. QD Visi- on occupies the entire building in Lexington, which houses the company’s global headquarters, as well as its production and development facilities.
QD Vision is currently working with several global consumer electronics companies that are building new products that employ its Quantum Light™ optics. For displays, QD Vision’s products provide greatly expanded color gamut simultaneously redu- cing manufacturing and operating costs while impro- ving system energy efficiency. For solid state lighting, its products enable LED lamps to produce incandes- cent-like, warm, white light with high efficiency.
uantum Materials Corporation (Pink Sheets: QTMM) and Nanoaxis, LLC announce the
formation of a technology alliance combining Quan- tum Materials tetrapod quantum dot mass produc- tion technology with Nanoaxis advanced research expertise and intellectual property in gene therapy biomedical nanotechnology. The aim of the alli- ance is to develop Tetrapod Quantum Dot based Cancer diagnostic kits and theranostic applications including Alzheimer‘s, Type 1 and Type 2 Diabetes, Breast Cancer and Major Depression.
Quantum Materials Corporation will develop spe- cialized quantum dots for Nanoaxis to functionalize with their proprietary biomedical nanomaterials for a multiplexing drug delivery platform for drug/gene therapy and diagnostic medical devices technologies. The technology alliance allows these technologies to be developed rapidly due to Quantum Materials‘ ability to create the highest quality quantum dots in quantities necessary to support multiple projects with timely deliveries.
The immediate goal is to develop a QD microarray device for detection, diagnosis and quantification of early cancers. The QD-MI device will be designed
19